Scenic Biotech

Scenic Biotech is a pioneering company in the field of genetic modifiers, focusing on the development of transformative therapeutics for devastating diseases, including inherited rare diseases and cancer. Founded in 2017 as a spin-out from the Netherlands Cancer Institute and Oxford University, the company operates in the biotechnology sector. Scenic Biotech's business model revolves around systematically exploring the human genome to identify disease-protecting genes, which can inspire new generations of therapeutics. The company collaborates with top-tier scientists and industry experts to advance its research and development efforts. Scenic Biotech generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its proprietary therapies. The company serves a global market, targeting pharmaceutical companies, healthcare providers, and patients in need of innovative treatments for rare and severe diseases.

Keywords: genetic modifiers, transformative therapeutics, rare diseases, cancer, biotechnology, genome exploration, disease-protecting genes, partnerships, licensing, commercialization.